多黏膜部位受累的结外边缘区淋巴瘤生存期短且转化频繁
该研究分析了1995至2017年405例结外边缘区淋巴瘤(EMZL)患者,其中43例(10.6%)表现为多黏膜部位(MMS)受累。MMS患者常伴有国际预后指数(IPI)>2(79.1%)、滤泡性淋巴瘤国际预后指数(FLIPI)>2(39.5%)和黏膜相关淋巴组织淋巴瘤国际预后指数(MALT-IPI)2-3(60.5%),且多因素分析显示MMS与更短的无进展生存(PFS)和总生存(OS)独立相关(HR分别为3.08和2.92),并具有更高的组织学转化(HGT)累积发生率。
要点
- MMS表现见于10.6%的EMZL患者,多见于年龄>60岁者(55.8%)。
- MMS患者中IPI>2、FLIPI>2和MALT-IPI 2-3的比例分别为79.1%、39.5%和60.5%。
- 多因素分析中MMS与更短PFS(HR=3.08)和OS(HR=2.92)独立相关。
核心结论
- EMZL患者中MMS表现代表一个新的临床亚群,与更短PFS、OS和更高HGT发生率相关,需要新的治疗方法。
研究设计与样本
- 分析1995年至2017年期间观察到的405例EMZL患者。
主要发现
- 265例(65.4%)患者初诊为I期疾病,309例中49例(15.8%)有骨髓受累,328例中35例(10.7%)有单克隆丙种球蛋白病(MG)。
- 43例(10.6%)患者有MMS表现,其中年龄>60岁者占55.8%;28例MMS患者中5例(17.9%)有MG。
- MMS患者常见IPI>2(79.1%)、FLIPI>2(39.5%)和MALT-IPI 2-3(60.5%)。
- 单因素分析中MMS表现和MG均与更短生存相关;多因素Cox回归中,MMS与更短PFS(HR=3.08)和OS(HR=2.92)相关,年龄≥60岁与更短PFS(HR=1.52)和OS(HR=2.45)相关,初始治疗后未达完全缓解与更短PFS(HR=3.27)和OS(HR=2.13)相关。
- 乳酸脱氢酶升高与更短PFS相关(HR=1.92),贫血与更短OS相关(HR=2.46);MALT-IPI≥2与更短PFS(HR=2.47)和OS(HR=4.75)相关,FLIPI>2与更短PFS(HR=1.65)和OS(HR=2.09)相关,IPI>2与更短PFS(HR=2.09)和OS(HR=1.73)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Between 11 and 37% of extranodal marginal zone lymphoma (EMZL) patients present with disease involvement in multiple mucosal sites (MMS). We analyzed 405 EMZL patients seen between 1995 and 2017: 265 (65.4%) patients presented with stage I disease, 49 of 309 (15.8%) patients with bone marrow involvement, and 35 of 328 (10.7%) patients with monoclonal gammopathy (MG). Forty-three (10.6%) patients had MMS presentation, which was more frequently seen in patients aged >60 years (55.8%). Five (17.9%) of 28 MMS patients had MG. MMS patients commonly exhibited the International Prognostic Index (IPI) >2 (79.1%), Follicular Lymphoma International Prognostic Index (FLIPI) >2 (39.5%), and Mucosa-Associated Lymphoid Tissue Lymphoma International Prognostic Index (MALT-IPI) 2-3 (60.5%). Both MMS presentation and MG were associated with shorter survival univariately. In multivariable Cox regression models, shorter progression-free survival (PFS) and overall survival (OS) were observed in patients with MMS (hazard ratio [HR] = 3.08 and 2.92, respectively), age ≥60 years (HR = 1.52 and 2.45, respectively), and in patients who failed to attain a complete remission following initial therapy (HR = 3.27 and 2.13, respectively). Elevated lactate dehydrogenase was associated with shorter PFS (HR = 1.92), while anemia (HR = 2.46) was associated with shortened OS. MALT-IPI ≥2 (HR = 2.47 and 4.75), FLIPI >2 (HR = 1.65 and 2.09), and IPI >2 (HR = 2.09 and 1.73) were associated with shorter PFS and OS, respectively. Higher grade transformation (HGT) occurred in 11 (25.6%) MMS patients with a 5-year cumulative incidence of 13.2% (95% CI 4.7-26.1%). EMZL patients with MMS presentation represent a novel clinical subset associated with shorter PFS, OS, and higher incidence of HGT that needs novel therapeutic approaches.
引用
- Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019. PMID: 30784098. doi:10.1002/ajh.25446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。